304 results on '"Monostory, Katalin"'
Search Results
2. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients
3. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma
4. The Prognostic Role of CYP Enzyme in Kidney Transplantation: A Single Centre Experience
5. CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function
6. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2
7. End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s
8. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
9. Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects
10. PK/PD investigation of antiviral host matriptase/TMPRSS2 inhibitors in cell models.
11. Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction
12. Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors
13. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure
14. Environmental risk assessment of human and veterinary medicinal products - Challenges and ways of improvement
15. Is CYP2D6 phenotype predictable from CYP2D6 genotype?
16. Utility of in vitro clearance in primary hepatocyte model for prediction of in vivo hepatic clearance of psychopharmacons
17. Robust and sensitive LC/MS-MS method for simultaneous detection of acetylsalicylic acid and salicylic acid in human plasma
18. Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia
19. Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients
20. Metabolic Drug Interactions with Immunosuppressants
21. Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone
22. In Vitro Pharmacokinetic Behavior of Antiviral 3-Amidinophenylalanine Derivatives in Rat, Dog and Monkey Hepatocytes
23. An algorithm for rapid computational construction of metabolic networks: A cholesterol biosynthesis example
24. Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor
25. Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression
26. Interplay between cholesterol and drug metabolism
27. Perspectives of the non-statin hypolipidemic agents
28. CYP1A2 mRNA Expression Rather Than Genetic Variants Indicate Hepatic CYP1A2 Activity
29. Legacy and Emerging Pollutants in an Urban River Stretch and Effects on the Bacterioplankton Community
30. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients
31. Clinical significance of CYP2C9-status guided valproic acid therapy in children
32. Combined gas chromatographic/mass spectrometric analysis of cholesterol precursors and plant sterols in cultured cells
33. Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes
34. Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s
35. Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes
36. Thein vitro biosynthesis and stability measurement with agyl-glycuronide isoformes of the main metabolite of ipriflavone
37. Acute heart transplantation from mechanical circulatory support in a human immunodeficiency virus‐positive patient with fulminant myocarditis
38. MONITORING LIVER-GRAFT DRUG METABOLZING CAPACITY USING PERIPHERAL BLOOD SAMPLE. CYP-PHENOTYPE AND GENOTYPE FREQUENCIES OF CYP2C9, CYP2C19, CYP3A4 AND CYP3A5: O-293
39. Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A‐status in liver transplant recipients
40. The ELIXIR Human Copy Number Variations Community: building bioinformatics infrastructure for research
41. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism
42. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors
43. Biochemical background of toxic interaction between tiamulin and monensin
44. Upregulation of cyp2e1 and cyp3a activities in histamine-deficient histidine decarboxylase gene targeted mice
45. A study on CYP1A inhibitory action of E-2-(4′-methoxybenzylidene)-1-benzosuberone and some related chalcones and cyclic chalcone analogues
46. Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles
47. Reduction of Toxic Metabolite Formation of Acetaminophen
48. Intrastrain and interstrain variability in biotransformation enzyme activities of rainbow trout (Oncorhynchus mykiss)
49. The Effect of Dexamethasone on P450 Activities in Regenerating Rat Liver
50. Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A‐status in liver transplant recipients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.